Correction to: Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma

Kyoko Nohara, Kazuhiko Yamada, Leo Yamada, Teruki Hagiwara, Toru Igari, Chizu Yokoi, Daisuke Soma, Satoshi Yamashita, Taeko Dohi, Yuki I. KawamuraGeneral 2018 · DOI · OpenAlex

Introduction

This article provides a formal correction to a previous study investigating the expression of kallikrein-related peptidase 13 (KLK13) and its association with prognosis in esophageal squamous cell carcinoma (ESCC). ESCC is a highly aggressive malignancy, and identifying reliable molecular markers is crucial for predicting patient outcomes. KLK13, a member of the kallikrein-related peptidase family, is involved in tissue remodeling and cell signaling, making it a candidate of interest in cancer research. This correction rectifies the foundational data in Figure 1, ensuring the scientific record accurately reflects the experimental evidence supporting the study's conclusions.

Methodology

The study employed a paired sample approach to compare KLK13 levels in cancerous tissues against normal esophageal mucosa from the same 24 patients. This design helps control for individual genetic variability. Two primary laboratory techniques were utilized:

  1. RT-PCR (Reverse Transcription-Polymerase Chain Reaction): Used to quantify mRNA transcript levels, allowing researchers to measure gene activity.
  2. Immunohistochemistry (IHC): Used to visualize the spatial distribution and presence of the KLK13 protein within tissue sections, providing context within the complex architecture of the esophagus.
IHC staining of KLK13 in normal esophageal mucosa shows robust protein expression.

Results and Discussion

The corrected data confirms a significant downregulation of KLK13 in ESCC at both the transcript and protein levels. Quantitative analysis via RT-PCR revealed that KLK13 transcript levels were markedly lower in cancerous tissues compared to normal mucosa, with a highly significant p-value of $P < 0.0001$. This trend was consistent across nearly all 24 patient samples analyzed, as shown in the relative expression data.

Spaghetti plot showing the significant decrease in KLK13 transcript expression from normal to cancerous (Ca) tissue.

Complementary IHC analysis supported these findings. While normal esophageal tissue exhibited clear and robust KLK13 staining, many ESCC specimens showed a substantial loss or sporadic presence of the protein. This loss of KLK13 expression suggests its potential role as a prognostic biomarker, where reduced levels may correlate with more aggressive disease progression. Establishing this downregulation is a critical step in understanding whether KLK13 acts as a tumor suppressor in the esophageal environment.

Conclusion

The rectification of Figure 1 ensures that the study's primary evidence—the consistent loss of KLK13 in ESCC—is accurately presented. While the results are statistically significant, further research in larger cohorts is necessary to validate KLK13 as a clinical biomarker and to elucidate the biological mechanisms by which its loss contributes to poor prognosis in esophageal cancer patients.

Summary updated

BibTeX
@inproceedings{nohara2018correction,
  author = {Kyoko Nohara and Kazuhiko Yamada and Leo Yamada and Teruki Hagiwara and Toru Igari and Chizu Yokoi and Daisuke Soma and Satoshi Yamashita and Taeko Dohi and Yuki I. Kawamura and Yuki Kawamura},
  title = {{Correction to: Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma}},
  booktitle = {General},
  year = {2018},
  doi = {10.1007/s11748-018-0923-0},
}
Figure